Tesamorelin — Egrifta & Compounding
Tesamorelin: FDA-approved as Egrifta for HIV-associated lipodystrophy, current compounding availability and off-label considerations.
Evidence-based answer
Tesamorelin: FDA-approved as Egrifta for HIV-associated lipodystrophy, current compounding availability and off-label considerations.
Regulatory status: Tesamorelin is FDA approved as Egrifta SV for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved as a general anti-aging or routine weight-loss drug.
Is tesamorelin or sermorelin FDA-approved?
Tesamorelin is FDA-approved as Egrifta SV and Egrifta WR, but only to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, so its trial results do not cover general fat loss, anti-ageing or muscle gain as of October 15, 2026. Sermorelin was approved as Geref, which is now discontinued; FDA found it was not withdrawn for safety or effectiveness, and no approved sermorelin product is currently marketed. Compounded sermorelin is sold online, but no current approved label or recent trial supports the anti-ageing uses it is marketed for.
Canonical answer dated October 15, 2026; the same text appears on our answers page.
How it works
Tesamorelin is a growth-hormone-releasing factor analog that stimulates pituitary growth hormone and increases IGF-1.
Mechanism is context, not proof. A defensible claim requires human outcome data for the exact molecule, formulation, dose and population. Receptor activity alone cannot establish how much weight a patient will lose, whether an injury will heal or whether a compounded vial has the identity and potency of a trial product.
What the clinical evidence shows
Randomized trials support reduction of visceral adipose tissue in HIV-associated lipodystrophy. That indication cannot be generalized to cosmetic fat loss or bodybuilding.
| Study or evidence level | Population | Intervention | Main result | Interpretation |
|---|---|---|---|---|
| Evidence grade | Varies by molecule | Exact product and route required | See primary sources | Do not extrapolate animal or mechanism data to human outcomes |
Clinical-use framework
Use follows the approved product label and reconstitution instructions; compounded wellness protocols are a different regulatory and evidence category.
A safe plan includes medical history, medication reconciliation, pregnancy screening where relevant, contraindication review, a written titration or administration schedule, missed-dose instructions, side-effect escalation and follow-up. Laboratory testing is individualized; a universal panel is not evidence-based for every patient, but clinicians may order testing based on symptoms, comorbidities and the medicine considered.
How to evaluate an online program
- Identify the legal entities. The marketing company, prescribing practice and dispensing pharmacy may be different organizations.
- Confirm the clinician. Look for a full name, credential, NPI where applicable and authority to practice in the patient’s state.
- Read the prescription label. Verify the exact drug, salt or base, concentration, directions, facility and beyond-use date.
- Normalize cost. Add medication, membership, visits, labs, supplies, shipping and dose surcharges.
- Match the evidence. Ask whether the offered dose and route were studied for the claimed outcome.
- Review continuity. Understand refills, cold-chain handling, replacement, pharmacy changes and cancellation.
Safety
Labeling addresses malignancy, elevated IGF-1, fluid retention, glucose intolerance, hypersensitivity and pregnancy. Monitoring is indication specific.
This page is educational and does not replace diagnosis or individualized prescribing. Severe symptoms, suspected overdose or a serious allergic reaction require urgent in-person evaluation.
Frequently asked questions
Is tesamorelin FDA approved?
Tesamorelin is FDA approved as Egrifta SV for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved as a general anti-aging or routine weight-loss drug.
What is the strongest evidence for tesamorelin?
Randomized trials support reduction of visceral adipose tissue in HIV-associated lipodystrophy. That indication cannot be generalized to cosmetic fat loss or bodybuilding.
Can a compounded or microdose product claim the same trial result?
Not automatically. The trial result applies most directly to the studied product, dose, titration, population and duration. A different formulation, route or lower dose requires its own evidence.
What should be verified before treatment?
Verify the exact product, indication, prescriber, pharmacy, concentration, dose schedule, recurring cost, commitment, follow-up plan and urgent-care instructions.
Primary sources
- Egrifta SV prescribing information Primary clinical or regulatory source
Provider marketing can document what is offered; it is not used as proof of safety or comparative effectiveness. Evidence was reviewed through July 12, 2026.